Immune from the worst case?

Finding that one's corporate partner has been acquired by another company always must raise concerns, as acquirers inevitably cull through the pipeline of the merged company. A case in point is The Immune Response Corp., which last year received $14.2 million of its $17.7 million in revenues from Agouron Pharmaceuticals Inc. through their collaboration to develop IMNR's Remune immunotherapeutic for HIV.

IMNR (Carlsbad, Calif.) believes it has little to worry about from the planned acquisition of AGPH by Warner-Lambert Co. because it brings a late-stage compound to the party. Remune, a gp120-depleted whole virus immunogen, is intended to stimulate a T cell response against the core proteins of HIV...